Post on 16-Dec-2015
transcript
June 2009
ECI Biotech
ECI Biotech is a premier developer of ExpressDetect® Diagnostics.
ExpressDetect® Diagnostics are simple, inexpensive, rapid, and safe.
ECI has development agreements with industry leaders in Consumer and Professional Health Care.
ECI Biotech has secured an aggregate of $18M in development funding, grants, and private equity.
June 2009
Funding History
Equity Financing $7.5 M
Collaborative Seed and Growth Partners, LLC
Vik Brothers International
The GS Fuller Foundation
Corporate Development Funding $5.0 M
Grants Phase I and II SBIR $1.9 M
June 2009
Current FundingCurrent Funding
Corporate Development Funding
Current $1M
SBIR Grants Project AwardedYeast Diagnostic $200,870PoC Wound Diagnostic, Phase I $208,311Therapeutic Agent for Periodontal Disease, years 1+2 $242,072PoC Wound Diagnostic, Phase II $949,000
Project PendingDetecting Trauma Induced Wound Infections $689,000Yeast Diagnostic Phase II $1,000,000Theranostic Grant $269,000
June 2009
QuickTime™ and aTIFF (Uncompressed) decompressorare needed to see this picture.
A series of high impact, low-cost, fast turnaround assays
ExpressDetect® Technology Summary
QuickTime™ and aTIFF (Uncompressed) decompressorare needed to see this picture.
Wound Care
Oral Care
Women’s Care
UTI
June 2009
Primary Markets
$2.9 B Wound Care Market 9.2% (CAGR)1. PoC for Clinics & Hospitals
2. Dressing sensor (Home health, VA, and nursing homes)
3. Consumer Band aids
4. Military Product for Combat Casualty Care
$2.9 B Oral Care Market (Cleaners/Whiteners/Dentures) 4.9% (CAGR)
1. Consumer Strep Diagnostic
2. Consumer and Professional Gingivitis
3. Consumer and Professional Periodontitis
Partner
Partner
Partner
Partner
June 2009
Secondary Markets
$1 B Women’s Health 16.6% (CAGR)
1. Yeast Diagnostic
2. BV-Tric-Yeast Consumer and Professional Care
$3 B UTI Diagnostic 40% (CAGR)1. Consumer UTI
2. Foley Catheter Market
Partner
Partner
June 2009
reportermolecules
anchor
peptidesubstrate
Diagnostic Assay Formats
Peptide covalently attached to microbead anchor and reporter molecule
PRESENTABSENT
PATCH
PoC QuickTime™ and aTIFF (Uncompressed) decompressor
are needed to see this picture.
June 2009
ExpressDetect® Assay Technology
Interaction Separation Detection
dual affinity tag
peptide
bead bead
minutes
June 2009
Market SizeMarket Size
Advanced Wound Care is a $2.8 B Industry
14M Chronic Wounds Treated Annually
Each patient is checked 8-10 x for infection
Market Opportunity ($840M)
Additional Market (50M Acute Wounds)
Biopsy
Visual exam only
Swab
35%
53%
12%
June 2009
Unmet NeedUnmet Need
Wounds need to be tested for bacterial load before
treatment
Visual Assessment Methods Inaccurate
Current methods take 2-3 days to get results
June 2009
Value PropositionValue Proposition
Our test takes 10 minutes
Low cost $16 (vs. $75 swab or $225 biopsy),
simple, and safe
Next steps, pre IDE meeting, clinical studies, and
launch
1.0E+01
1.0E+02
1.0E+03
1.0E+04
1.0E+05
1.0E+06
1.0E+07
1.0E+08
1.0E+09
1.0E+10
1 10 100 1000 10000
ng peptide clipped (0.1 ml sample)
diabetic
pressure
venous
post-acute
undefined
3.0E+05 CFU/mlcutoff
45 ng peptidecutoff
June 2009
Time Course of Color Reaction
Dressing Sensor Time Course with A. baumannii. In the presence of culture media (BHI) or BHI + A. baumannii incubated for 0, 20, 40, or 60 minutes. Blue color indicates the presence of the pathogen. Scale Bar = 4 cm.
QuickTime™ and aTIFF (LZW) decompressor
are needed to see this picture.
June 2009
Unique FunctionalityUnique Functionality
Inexpensive (COGS<3 cents), and safe enough for
band-aids
Sensor turns blue when infection is likely
June 2009
Proof of ConceptProof of Concept
Detection of Common Wound Pathogens
Threshold is > 106 CFU/mL
Top five bacteria with CPI2S
0
0.5
1
1.5
2
2.5
3
3.5
4
0 100 200 300 400 500
Time (sec)
OD 650 nm
S. aureusP. mirabilisP. aeruginosaE. faecalisS. pyogenesControl
1
10
100
1000
10000
UWI 021UCO 025UWI 023UCO 021UTS 021control
UTS 010UCO 006UCLA 004UWI 008UNC 005
controlUCO 001UCLA 017UCO 002UCO 005UTS 001
controlUTS 013UWI 013UCO 015UWI 011
UCLA 021
controlHUP 079
UMMH 202UMMH 203
control
slope of color change
(mU A405/min)
P. aeruginosa S. aureus E. faecalis S. pyogenes P. mirabilis
June 2009
Intellectual PropertyIntellectual Property
Strong IP with 18 patent families issuing world-
wide
Additional design patents in preparation (See
IP doc)
June 2009
510 (k) and CLIA Guidance510 (k) and CLIA Guidance
Clear regulatory path with FDA
Time for Pre-IDE meetings
June 2009
CompetitionCompetition
ExpressDetect® Antibody Visual Signs CultureReal Time X Specificity X
Low Cost $16 $16+ $75-$225
Broad Spectrum X
Active Detection X ?
June 2009
RevenueRevenue
Chronic Wound Opportunity for ECI = $840 Million14M wounds; 4 tests/wound; $15/test
2008 2009 2010 2011 2012Revenue (000) 793 515 2,453 12,691 23,859EBITDA (1,049) (2,056) (1,412) 4,474 12,339Pretax/Net Income (1,223) (2,693) (1,706) 4,015 9,146
June 2009
ECI Organization Chart
David FogelCFO
Tara Shariff, MBADir. of Buisness Development
G&A
Barbara AppiahClinical Research
Linsay Poland MSRobotics and HTS Library Specialist
Jennifer EwaltChemistry
Courtney Mayo, Ph.D.Biochemistry and Molecular Scientist
Shelley Doughtery, PhDPolymer Scientist
Andrei Rakitin, PhDPhysicist/Statistics
Geert Cawenbergh, Ph.D.Director of Scientific Advisors & BOD
R&D
VP of China OperationsZhong Zhang
VP of US OperationsDale Macy,
Manufacturing
Mitchell Sanders, PhDCEO and Founder